6W6Aeg3W3E | 159730-07-1

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 6W6Aeg3W3E
• 英文别名: 1-[(3,4-dimethoxyphenyl)methyl]-6-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
• CAS: 159730-07-1
• 化学式: C₂₁H₂₄N₂O₂
• 分子量: 336.4
• InChiKey: GDAJGLDMCDMPIR-UHFFFAOYSA-N

物化性质

• 沸点：
  524.3±45.0 °C(Predicted)
• 密度：
  1.170±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• COMPOUNDS FOR TREATMENTS OF INFLAMMATION
  申请人：Palmqvist Niklas

  公开号：US20120190751A1

  公开（公告）日：2012-07-26

  The present invention relates to the use of benzylideneaminoguanidines for the treatment of inflammation and pain. In one preferred embodiment, the invention relates to the use of N-(2-chloro-3,4-dimethoxybenzylideneamino)guanidine for the treatment of rheumatoid arthritis.

  本发明涉及使用苯甲醛胍基胍类化合物治疗炎症和疼痛。在一个优选实施例中，本发明涉及使用N-(2-氯-3,4-二甲氧基苯甲醛基)胍基胍治疗类风湿性关节炎。
• COMBINATION TREATMENT OF SPECIFIC FORMS OF EPILEPSY
  申请人：ZOGENIX INTERNATIONAL LIMITED

  公开号：US20170071949A1

  公开（公告）日：2017-03-16

  Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed. The formulations comprise a 5-HT receptor agonists which does not agonize selected 5-HT receptor subtypes, and in particular does not agonize the receptor subtype 5-HT2B. Also disclosed are combinations of such 5-HT receptor agonists. Also disclosed are combinations of such 5-HT receptor agonists and SSRIs, SNRIs, and triptans for treating co-morbidities associated with Dravet syndrome.